The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback